Findings

What do systematic reviews say?

5 questions · 7 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 14.3%Moderate 6 · 85.7%High 0 · 0%

Failure to induce clinical remission at end of study · patients with induction of remission in ulcerative colitis

Etrolizumab probably leads to lower failure to enter clinical remission at week 10 compared with placebo (moderate certainty).

2 findings from 1 review

Etrolizumab for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
RR 0.86 [0.77, 0.95]
1 study · 119 participants
Moderate
Etrolizumab for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
RR 0.81 [0.68, 0.96]
1 study · 59 participants
Moderate

Failure to respond at endpoint (6‐12 weeks) · patients with induction of remission in ulcerative colitis

Etrolizumab showed no clear difference in failure to respond at week 10 compared with placebo (moderate certainty).

1 finding from 1 review

Etrolizumab for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
RR 0.96 [0.75, 1.23]
1 study · 119 participants
Moderate

Failure to induce endoscopic remission · patients with induction of remission in ulcerative colitis

Etrolizumab showed no clear difference in failure to enter endoscopic remission at week 6 compared with placebo (moderate certainty).

2 findings from 1 review

Etrolizumab for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
RR 0.98 [0.9, 1.06]
1 study · 119 participants
Moderate
Etrolizumab for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
RR 0.92 [0.85, 1]
1 study · 119 participants
Moderate

Adverse events · patients with induction of remission in ulcerative colitis

Etrolizumab probably leads to lower adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Etrolizumab for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
RR 0.75 [0.57, 0.99]
1 study · 124 participants
Moderate

Serious adverse events · patients with induction of remission in ulcerative colitis

Etrolizumab showed no clear difference in serious adverse events compared with placebo (low certainty).

1 finding from 1 review

Etrolizumab for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
RR 0.92 [0.36, 2.34]
2 studies · 165 participants
Low